Ibogaine Shown to Alter Brain Rhythms and Boost Mental Health in Veterans with TBI

A New Insight into Ibogaine’s Potential for Traumatic Brain Injury

A recent study published in Nature Mental Health has uncovered initial evidence that the psychedelic compound ibogaine may influence brain activity and alleviate psychiatric symptoms in individuals with a history of traumatic brain injury (TBI). The research, conducted on a group of combat veterans, revealed that magnesium-ibogaine therapy was associated with changes in cortical oscillations and neural complexity—both of which were linked to improvements in cognitive functioning, post-traumatic stress, and anxiety. These findings provide a rare glimpse into the neural effects of ibogaine in humans and suggest that altered brain rhythms might play a key role in its therapeutic potential.

Ibogaine is a psychoactive alkaloid derived from the root bark of the Tabernanthe iboga shrub, native to Central Africa. Traditionally used in spiritual ceremonies, it has gained attention for its potential therapeutic properties, particularly in treating substance use disorders. More recently, anecdotal reports and small studies have indicated that it may help with symptoms related to TBI, such as anxiety, depression, cognitive dysfunction, and post-traumatic stress.

Unlike classic psychedelics like psilocybin or LSD, ibogaine is classified as oneirogenic, meaning it tends to produce immersive, dream-like states accompanied by extended periods of self-reflection. Its effects are long-lasting and pharmacologically complex, interacting with various brain targets including serotonin and dopamine transporters, opioid receptors, and the N-methyl-D-aspartate system. Despite this broad interaction, little is known about how ibogaine alters human brain function.

To address this gap, researchers at Stanford University, led by Jennifer I. Lissemore, Corey J. Keller, and Nolan R. Williams, conducted a prospective study to explore how a single session of magnesium-ibogaine therapy might affect brain activity. They focused on two neural features commonly altered by brain injury: cortical oscillations and neural complexity.

The study involved 30 male veterans who had served in Special Operations Forces and had documented histories of TBI. Most participants reported psychiatric diagnoses, including PTSD, depression, anxiety, and alcohol use disorder. Before treatment, they stopped taking medications that could interfere with ibogaine. They then traveled to a facility in Mexico, where they received oral ibogaine combined with intravenous magnesium sulfate—a formulation designed to reduce cardiovascular risks.

EEG scans were conducted before treatment, three and a half days afterward, and one month later. Participants were asked to keep their eyes open and remain awake while letting their minds wander. The data showed changes in brain activity, including increased power in slower oscillations (theta and alpha) and decreased power in faster oscillations (beta and gamma). This shift toward slower activity correlated with improvements in executive functioning and reductions in PTSD and anxiety symptoms.

Another key finding was a reduction in peak alpha frequency, which persisted even one month after treatment. Lower peak alpha frequency was associated with reduced stress and anxiety. Neural complexity, measured by Lempel–Ziv complexity, also decreased after treatment, suggesting more stable brain signals. This reduction was linked to improved executive functioning, especially in those with lower complexity at baseline.

Some of these effects remained present one month after treatment, indicating that ibogaine may lead to lasting changes in brain organization. The study also found that individuals with lower peak alpha frequency and lower neural complexity at baseline tended to benefit more from treatment, suggesting that EEG patterns could predict treatment response.

Although the results are promising, the study was not a randomized controlled trial, and there was no placebo group. This makes it difficult to rule out factors like expectancy or coaching. Additionally, the sample was highly specific, consisting of male Special Operations veterans with high TBI exposure, which limits generalizability.

Despite these limitations, the magnitude and persistence of the observed changes provide a strong rationale for follow-up trials using more rigorous designs. The findings suggest that ibogaine may offer a new path forward for treating complex post-TBI symptoms in veterans, especially when other therapies have failed.

“Ibogaine is a powerful compound that should not be used outside of medically supervised settings,” Lissemore emphasized. “Clinicians should view these findings as promising early evidence that a therapeutic shift in brain state may be achievable in a single ibogaine session, but further research and regulatory steps are needed before clinical use.”

The study, titled “Magnesium–ibogaine therapy effects on cortical oscillations and neural complexity in veterans with traumatic brain injury,” was authored by Jennifer I. Lissemore, Anna Chaiken, Kirsten N. Cherian, Derrick Buchanan, Flint Espil, Jackob N. Keynan, Malvika Sridhar, Camarin E. Rolle, Manish Saggar, Corey J. Keller, and Nolan R. Williams.